



- (51) **International Patent Classification:**
Not classified
- (21) **International Application Number:**
PCT/US2024/024829
- (22) **International Filing Date:**
16 April 2024 (16.04.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|-------------------------------|----|
| 63/459,986 | 17 April 2023 (17.04.2023) | US |
| 63/502,639 | 16 May 2023 (16.05.2023) | US |
| 63/592,495 | 23 October 2023 (23.10.2023) | US |
| 63/608,114 | 08 December 2023 (08.12.2023) | US |
| 63/623,756 | 22 January 2024 (22.01.2024) | US |
| 63/553,520 | 14 February 2024 (14.02.2024) | US |
- (71) **Applicant: BE BIOPHARMA, INC.** [US/US]; One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US).
- (72) **Inventors: MULLEN, Timothy James;** c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **LIU, Hanlan;** c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **HOHMANN, Anja Fides;** c/o Be Biopharma, Inc., One

Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **ARLAUCKAS, Sean Philip Leary;** c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **SINGH, Swati;** c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **KEEGAN, Sean Patrick;** c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **MORGAN, Richard A.;** c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US).

- (74) **Agent: ADAMS, Melissa M.** et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

- (54) **Title:** ENGINEERED CELL PREPARATIONS FOR TREATMENT OF HEMOPHILIA

p00573 AMT061

MND	AMT061 (Padua)	BGHpA
-----	----------------	-------

p00576 Zero CG.AH

MND	co-FIX AH (Padua)	BGHpA
-----	-------------------	-------

p00577 Zero CG.SS

MND	co-FIX SS (Padua)	BGHpA
-----	-------------------	-------

FIG. 1

- (57) **Abstract:** The present disclosure provides methods and compositions for culturing, engineering, and administering engineered B lineage cell populations that produce Factor IX (FIX).

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*